Table 3.

Adverse event summary: total population.

Adverse events	PL		NB
	DPP4 (n = 317)	GLP1 (n = 316)	DPP4 (n = 345)	GLP1 (n = 339)
Serious AE	29 (9.1%)	35 (11.1%)	46 (13.3%)	42 (12.4%)
Severe AE	16 (5.0%)	18 (5.7%)	28 (8.1%)	32 (9.4%)
Mild AE	7 (2.2%)	12 (3.8%)	35 (10.1%)	38 (11.2%)
Study-drug-related	15 (4.7%)	9 (2.8%)	57 (16.5%)	65 (19.2%)
AEs with frequency ≥1% in any treatment group, n (%)

Body system	AE	PL		NB
		DPP4 (n = 317)	GLP1 (n = 316)	DPP4 (n = 345)	GLP1 (n = 339)
Cardiac	Unstable angina	1 (0.3%)	2 (0.6%)	4 (1.2%)	8 (2.4%)
Gastrointestinal	Constipation	–	–	7 (2.0%)	7 (2.1%)
	Diarrhea	1 (0.3%)	1 (0.3%)	2 (0.6%)	4 (1.2%)
	Nausea	2 (0.6%)		24 (7.0%)	32 (9.4%)
	Vomiting	–	–	5 (1.4%)	10 (2.9%)
General disorders	Non-cardiac chest pain	–	2 (0.6%)	1 (0.3%)	5 (1.5%)
Musculoskeletal/connective tissue	Osteoarthritis	1 (0.3%)	6 (1.9%)	–	4 (1.2%)
Nervous system	Headache	–	1 (0.3%)	–	4 (1.2%)
	Tremor	–	–	4 (1.1%)	8 (2.4%)